Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells

Status:	Recruiting
Conditions:	Prostate Cancer, Hematology, Benign Prostate Hyperplasia, Urology
Therapuetic Areas:	Hematology, Nephrology / Urology, Oncology
Healthy:	No
Age Range:	Any
Updated:	3/10/2019
Start Date:	March 2015
End Date:	March 2019

Optimizing Human Prostate Extracellular Matrix as a Structure for Maintenance and Studying of Prostate Cancer Stem Cells

This pilot research trial studies the use of a human prostate tissue model to maintain and
study prostate cancer stem cells. A human prostate tissue model uses leftover tissue that was
removed during surgery from patients with non-cancerous enlargement of the prostate (benign
prostatic hyperplasia) and may create an environment similar to the natural environment of
the human body. Prostate cancer stem cells are cells that cause cancer to grow. Using real
tissue to create an environment to study stem cells may help doctors learn more about how
they work and how they respond to treatments.

PRIMARY OBJECTIVES:

I. To optimize a decellularized prostate tissue model for the maintenance of prostate cancer
stem cells.

SECONDARY OBJECTIVES:

I. To investigate the self-renewal and differentiation ability of human prostate cancer stem
cells (CSCs) (tumor-associated calcium signal transducer 2 [TROP2]+ cells) in the above
mentioned decellularized prostate tissue model.

II. To compare the number of CSCs according to key patient characteristics, including race,
age, Gleason, metastasis status, and previous cancer treatment(s).

OUTLINE:

Tissue samples are collected from patients with benign prostatic hyperplasia for
decellularization and preparation as human extracellular matrix for growing human prostate
CSCs. Tissue samples are also collected from patients with prostate cancer for the analysis
of TROP2+ cells by flow cytometry.

Inclusion Criteria:

- Male patients scheduled for a prostatectomy

- Ability to understand and the willingness to sign an Institutional Review Board
(IRB)-approved informed consent document

Exclusion Criteria:

- Patients with prostate involvement secondary and as a result of metastasis or spread
of cancerous cells from other organs

We found this trial at

sites

Comprehensive Cancer Center of Wake Forest University

Medical Center Boulevard
Winston-Salem, North Carolina 27157

336-716-2255